Angel investors in life sciences firms have not only filled a void left by skittish venture capitalists, they offer entrepreneurial expertise and fundraising networks that can carry startups through the so-called valley of death, writes Jeremy Halpern, a partner with law firm Nutter McClennen & Fish. "Leveraging an angel's expertise can be a critical aid to decrease the process time of fundraising and to maximize the potential capital raise[d] to meet the high needs of life science ventures," he writes. Universities, state governments, Big Pharma and private foundations have also begun to delve into early-stage investing, Halpern writes.

Full Story:

Related Summaries